SPONSORED

About 30 Million Tests a Week May Be Needed to Reopen Communities(1)

This Possible $157 Billion “Testing Economy” Could Give Medivolve (NEO:MEDV)(OTC:COPRF) a Big Shot in the Arm(1)

News Update April 6, 2021:

Medivolve Subsidiary Collection Sites Provides March Sales Update With Total Sales of 20,574 Tests at an Average Price of $99 per Test

Like me, you’re exhausted from hearing about the health scare.

We’re exhausted from the lockdowns, from social distancing, from having to wear masks.

Many of us are burning out from it, claim psychologists. Many people seem to be feeling worn out and unable to mentally cope with the issue. Others believe the health scare will be around longer than expected. There appear to be dashed hopes of easing restrictions and increased fatigue.

“Emotional exhaustion is this sense of overwhelmingness — overwhelmed to the point where you feel like you don’t have the capacity to deal anymore,” says Vaile Wright, senior director of health care innovation for the American Psychological Association. “It’s physical tiredness. It’s mental tiredness. It’s difficulty concentrating. It’s all the things that we experience when we’re just at our capacity,” says the Chicago Sun-Times.(2)

But there’s good news. Eventually, we will undoubtedly get back to some sort of normal. But, to get to that point, we need more testing.

“We’ve gone from about 1 million to nearly 4.5 million tests per week in the U.S., but we’ll need to redouble our efforts to make it to approximately 30 million tests per week and beyond to reopen communities and economies and keep them open,” says The Rockefeller Foundation.(1)

That’s where a company like Medivolve Inc. (NEO:MEDV)(OTC:COPRF) comes into play.

The Top 12 Reasons to Consider Medivolve (NEO:MEDV)(OTC:COPRF) Right Now 

  1. The Rockefeller Foundation claims that we will need about 30 million tests a week to safely reopen communities.(1)
  2. Wells Fargo believes that the “testing economy” could be worth approximately $157 billion by 2022.(1)
  3. Medivolve’s subsidiary, Collection Sites, looks to be rolling out a large network of testing sites across the United States.(1)
  4. The company claims that it has also been partnering with major property owners, including Simon Property Group.(1)
  5. Collection Sites reportedly provides quick and convenient testing in conjunction with a CLIA registered lab, including rapid antigen, PCR, and rapid antibody tests with insurance options.(1)
  6. The company appears to have mobile sites for 10 minute RT-PCR, antigen, and antibody testing.(1)
  7. It can reportedly provide same-day results from Alcala Labs with nearly 98% accuracy on select tests.(1)
  8. The collection sites have the capacity to perform up to roughly 150 tests per cube a day at an average price of just less than about $100.(1)
  9. The company also seems to have a scalable business model with a low cost of customer acquisition
  10. “As cases continue to rise across the United States, Collection Sites testing centers are seeing increased demand from both consumers as well as businesses eager to offer testing to employees and customers,” says Doug Sommerville, CEO.(3)
  11. Medivolve has an outstanding management team with years of healthcare experience
  12. Members of Medivolve’s Medical Advisory Board are thought leaders, influencers, opinion makers, and leaders within their respective fields, areas of expertise, sector, and industry, including Dr. Glenn Copeland and Jim Rogers.(1)

Medivolve (NEO:MEDV)(OTC:COPRF) Has Healthy Technicals

Over the last several months, the stock appears to have broken from multi-month consolidation at around 14 cents a share to approximately 70 cents. After a brief pullback to about 40 cents, the stock seems to have caught double bottom support. With what looks to be far more testing required thanks to the health situation, Medivolve has the potential to see more momentum.

Plus, several of its technical indicators look positive, as well, including its 20 – 50 Day MACD Oscillator, 20 – 100 Day MACD Oscillator, 20 – 200 Day MACD Oscillator, 50 – 100 Day MACD Oscillator, 50 – 150 Day MACD Oscillator, 50 – 200 Day MACD Oscillator, 100 Day Moving Average, 150 Day Moving Average, 200 Day Moving Average, and 100 – 200 Day MACD Oscillator.(7)

Who is Medivolve (NEO:MEDV)(OTC:COPRF)?

Medivolve is a publicly-traded company that seeks out disruptive technologies, groundbreaking innovations, and exclusive partnerships to help combat the current health issue.

With a seasoned executive team and renowned global advisors that provide expertise across industries, Medivolve appears to offer shareholders diversified and cutting-edge exposure to the medical space across geographic regions and three focus areas: detection, prevention, and treatment.

It’s recently identified the “testing economy” as the most potentially lucrative.

Medivolve seems to believe that the “testing economy” could have lucrative potential. This appears to echo Wells Fargo’s claim that this medical subsector could be worth about $157 billion by 2022.(1)

With that being the case, the company’s subsidiary, Collection Sites, seems to have been rolling out hundreds of testing sites across the United States. It appears to be partnering with major real estate owners such as Simon Property Group, Sandor, H&S Energy Products, and others to accomplish this.(1)

Better, Collection Sites reportedly provides quick and convenient testing in conjunction with a CLIA registered lab, including rapid antigen, PCR, and rapid antibody tests with insurance options.

All to help millions get tested.

Furthermore, its average price per test at approximately $96 appears to be significantly more cost-effective than the median price for testing of about $127. About one in five tests also seems to cost more than about $200.(1)

In an effort to flatten the curve, the company:(1)

  • Has mobile site for 10 minute RT-PCR, antigen and antibody testing
  • Same day results from certified high complexity Alcala Labs – around 98% accuracy on select tests
  • Approximately 740+ locations throughout the United States
  • Can provide up to roughly 150 tests per cube per day at an average price just under $100
  • Has a scalable business model with low cost of customer acquisition

“As cases continue to rise across the United States, Collection Sites testing centers are seeing increased demand from both consumers as well as businesses eager to offer testing to employees and customers,” says Mr. Doug Sommerville, CEO. “Having now refined our operational model with the launch of the first 20 cubes, we are now ready to expand our network and get convenient and effective test results to everyday Americans so we can flatten the curve.”(5)

https://biotechmarketreporter.com/

Medivolve (NEO:MEDV)(OTC:COPRF) Acquired 100% of Noble Bioscience Corp and its Surface Shield Technology(6)

The company seems to have entered into an agreement to acquire 100% of Noble Bioscience Corp., which claims to hold the agency rights to Nuturell’s Surface Shield technology in the United States, Canada, and the Caribbean. Medivolve’s subsidiary Collection Sites, LLC will seemingly lead the United States sales effort on behalf of the company.(6)

“To return back to normal operation in this environment, people need the confidence that they will be safe as they move about,” stated Mr. Doug Sommerville, the CEO of Medivolve Inc. “By providing companies with a solution that eliminates any concern about contamination – from hotel rooms to grocery stores – consumers will be more comfortable using their services. We are excited to help distribute such a coating technology and believe the business applications, as well as consumers, are substantial and well worth the investment.”(6)

Nuturell’s Surface Shield technology was created to overcome the limitations of standard harsh chemical disinfectants and cleaning agents that suffer from various constraints such as their harmfulness, corrosive nature, and bacterial resistance. Nuturell’s surface shield claims that it can kill a broad range of pathogens in only about 30 seconds of contact and is considered a “green” surface shield. Silver has been well-known as an antimicrobial agent and for its medicinal importance due to the remarkable pathogen-killing properties.

Plus, the Medivolve (NEO:MEDV)(OTC:COPRF) Team Has Years of Experience

Douglas Sommerville — CEO

Doug has held prominent roles at pharmaceutical giants such as Teva Pharmaceuticals and Baxter Healthcare International. In this role as Head of Teva Canada, Mr. Sommerville was responsible for Teva’s third-largest global subsidiary, with sales of over roughly $1.3 billion. Doug was also the Chairman of the Canadian Generic Pharmaceutical Association until he retired from Teva Canada in 2018. He holds an MBA from the Schulich School of Business.

Deborah Battiston – CFO

Deborah Battiston is a CPACGA, she obtained her BA in Economics from the University of Guelph and holds an ICD.D from the University of Toronto’s Rotman School of Management. Deborah has an extensive background with over 25 years of financial management, including public companies, mergers and acquisitions, tax, and financing.

Aaron Atin – Corporate Secretary

Aaron Atin is a corporate and securities lawyer with extensive experience in securities, M&A, and corporate finance. He holds an engineering diploma from Centennial College, a Bachelor of Arts from the University of Waterloo, and a J.D. from the University of Toronto, Faculty of Law.

Dr. Beverley Richardson — Director

Dr. Beverley J. Richardson is a renowned psychotherapeutic practitioner whose collaborative efforts and clinical influence are reflected in some of the most compelling and effective addiction and behavioral health programs in North America, which include: Sierra Tucson (Arizona), the Meadows (Arizona), and Betty Ford Centre (California).  She has a Doctorate Degree in Psychology and is a B.C. Registered Clinical Counsellor, Internationally Certified Eating Disorder Specialist, and EMDR Level II Trauma Therapist. Dr. Richardson has integrated her extensive health and wellness experience with her entrepreneurial spirit to form her nutraceutical and bioscience research and development enterprises.

Daniyal Baizak – Director

Daniyal is a seasoned professional with considerable experience providing financial and strategic advice on mergers, acquisitions, and managing multiple projects for various private and public companies. With expertise in Central Asian and Russian markets, Daniyal plays a crucial role in navigating and finding new investment opportunities in frontier and emerging markets for F&M.

Wen Ye – Executive Chairman

Ms. Ye is a CPA, CGA, and holds a Bachelor of Commerce degree from Laurentian University. Ms. Ye brings over 17 years of corporate and finance management experience in the public mining, securities, and logistics sectors.

ADVISORY BOARD

Members of Medivolve’s Medical Advisory Board represent a unique brain trust. Comprised of thought leaders, influencers, opinion makers, and leaders within their respective fields, areas of expertise, sector, and industry – they are committed to Medivolve’s mission to bring medical breakthroughs to market with power, grace, and ease.

Members of the Medical Advisory Board will help fulfill Medivolve’s mission of searching for and investing in breakthrough sciences, technologies, research, or resolutions to empower the betterment of mankind.

Dr. GLENN COPELAND — ADVISOR

Possessing over 45 years of experience in orthopedic treatment and sports medicine, Dr. Glenn Copeland is one of North America’s most prominent foot and ankle specialists. Between 2002 and 2008, Dr. Copeland was selected to be the founder, Chairman, and CEO of Cleveland Clinic Canada. Cleveland Clinic is universally regarded as one of the top three medical institutions in the world.

Dr. JOSEPH SUGERMAN — ADVISOR

Dr. Sugerman is a board-certified otolaryngologist who manages a private practice in Los Angeles focused on managing voice disorders. He is a past Clinical Chief at Cedars-Sinai Medical Centre. He is also a former board member of MGM Mirage. Dr. Sugerman was a Clinical Instructor at the University of Southern California (USC) Keck School of Medicine and the University of California at Los Angeles (UCLA) Department of Otolaryngology: Head and Neck Surgery Division.

Dr. LAWRENCE STEINMAN — ADVISOR

Dr. Steinman is a Professor of Neurology, Neurological Sciences, and Paediatrics at Stanford University and was Chair of the Stanford Program in Immunology from 2001 to 2011. His research focuses on antigen-specific tolerance in autoimmune disease and in gene therapy for degenerative neurologic disorders. Dr. Steinman has elucidated what provokes relapses and remissions in multiple sclerosis (MS). He serves as an attending neurologist at Stanford’s Lucille Packard Children’s Hospital.

MICHAEL MCCARTHY

Mike is widely recognized across Canada as a health care champion and advocate. As a principal with Grosso McCarthy, Mike has over 15 years of experience with the Ontario Ministry of Health and Long Term Care and over 25 years in health policy and delivery. In 2001, he was appointed Senior Policy Advisor to the Ontario Minister of Health. Mike has also been on the front lines of health care, working for 18 years as a psychiatric nurse.

JIM ROGERS

Mr. Rogers co-founded the Quantum Fund, a global- investment partnership. After retiring – at age 37, Mr. Rogers continued to manage his own portfolio and serve as a finance professor at the Columbia University Graduate School of Business. Mr. Rogers also presciently saw the formation of the subprime mortgage crisis a year before it erupted.

MIKE MANCIAS

Mike has served as the Chief Performance Advisor to LeBron James for over 14 years and counting. His experience includes working with NBA, NFL, MLB, PGA, and top NCAA athletes. Mike attended the University of Texas- Pan American and graduated with a degree in Health Education. Mike is licensed and nationally certified by the Accredited National athletic Trainers Association and is a 14-year member of The National Basketball Athletic Trainers Association.

RICHARD DOLAN

Richard is an advocate and researcher on the subject of human betterment through effective and responsible investment. An internationally best-selling author and highly sought-after speaker, Richard has shared the stage with many former presidents.

The Top 12 Reasons to Consider Medivolve (NEO:MEDV)(OTC:COPRF) Right Now

  1. The Rockefeller Foundation claims that we will need about 30 million tests a week to safely reopen communities.(1)
  2. Wells Fargo believes that the “testing economy” could be worth approximately $157 billion by 2022.(1)
  3. Medivolve’s subsidiary, Collection Sites, looks to be rolling out a large network of testing sites across the United States.(1)
  4. The company claims that it has also been partnering with major property owners, including Simon Property Group.(1)
  5. Collection Sites reportedly provides quick and convenient testing in conjunction with a CLIA registered lab, including rapid antigen, PCR, and rapid antibody tests with insurance options.(1)
  6. The company appears to have mobile sites for 10 minute RT-PCR, antigen, and antibody testing.(1)
  7. It can reportedly provide same-day results from Alcala Labs with nearly 98% accuracy on select tests.(1)
  8. The collection sites have the capacity to perform up to roughly 150 tests per cube a day at an average price of just less than about $100.(1)
  9. The company also seems to have a scalable business model with a low cost of customer acquisition
  10. “As cases continue to rise across the United States, Collection Sites testing centers are seeing increased demand from both consumers as well as businesses eager to offer testing to employees and customers,” says Doug Sommerville, CEO.(3)
  11. Medivolve has an outstanding management team with years of healthcare experience
  12. Members of Medivolve’s Medical Advisory Board are thought leaders, influencers, opinion makers, and leaders within their respective fields, areas of expertise, sector, and industry, including Dr. Glenn Copeland and Jim Rogers.(1)
Source 1: https://medivolve.ca/pdf/Medivolve-Investor_Deck-31-Jan-9.58-am222.pdf
Source 2: https://chicago.suntimes.com/well/2021/1/29/22227020/emotional-exhaustion-cope-coping-depression-covid-pandemic-coronavirus-mental-health-wellness
Source 3: https://medivolve.ca/collection-sites-expands-convenient-covid-19-testing-across-america-with-25-additional-testing-sites/
Source 4: https://www.barchart.com/stocks/quotes/MEDV.NE/interactive-chart
Source 5: https://medivolve.ca/collection-sites-expands-convenient-covid-19-testing-across-america-with-25-additional-testing-sites/
Source 6: https://medivolve.ca/medivolve-enters-into-agreement-to-acquire-100-of-noble-bioscience-corp-and-its-agency-rights-to-nuturells-covid-19-surface-shield-technology/
Source 7: https://www.barchart.com/stocks/quotes/MEDV.NE/opinion
OTC:COPRF
NEO:MEDV
Company Contact

Address: 65 Queen Street West Suite 800 Toronto ON M5H 2M5 CA
Phone: +1 416 861-5888

What They Do

Medivolve Inc is an investment management company that offers a diversified investment option in the COVID-19 medical space across three areas; prevention, detection, and treatment. The focus of the company is to sell COVID-19 IgG/IgM antibody tests.